| Novel therapies are changing treatment paradigms in metastatic prostate cancer E Powers, GS Karachaliou, C Kao, MR Harrison, CJ Hoimes, DJ George, ... Journal of hematology & oncology 13, 1-13, 2020 | 101 | 2020 |
| LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types LC Brown, MD Tucker, R Sedhom, EB Schwartz, J Zhu, C Kao, ... Journal for immunotherapy of cancer 9 (3), 2021 | 78 | 2021 |
| High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better Prognosis in Ovarian Cancer Both In Vivo and In Vitro F Wang, JTH Chang, CJ Kao, RS Huang Molecular cancer therapeutics 15 (5), 1123-1131, 2016 | 60 | 2016 |
| COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy MM Daughety, A Morgan, E Frost, C Kao, J Hwang, R Tobin, B Patel, ... Thrombosis research 196, 483, 2020 | 38 | 2020 |
| Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma MD Tucker, LC Brown, YW Chen, C Kao, N Hirshman, EN Kinsey, ... Biomarker Research 9, 1-9, 2021 | 26 | 2021 |
| Predictive value of combining biomarkers for clinical outcomes in advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors C Kao, E Powers, Y Wu, MB Datto, MF Green, JH Strickler, NE Ready, ... Clinical lung cancer 22 (6), 500-509, 2021 | 19 | 2021 |
| Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab LC Brown, K Desai, W Wei, EN Kinsey, C Kao, DJ George, BI Rini, ... Journal for ImmunoTherapy of Cancer 9 (9), 2021 | 15 | 2021 |
| Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: a retrospective analysis of safety, tolerance, and clinical … AL Laccetti, B Garmezy, L Xiao, M Economides, A Venkatesan, J Gao, ... Cancer medicine 10 (7), 2341-2349, 2021 | 13 | 2021 |
| A multi-institutional, retrospective analysis of patients with metastatic renal cell carcinoma to bone treated with combination ipilimumab and nivolumab K Desai, L Brown, W Wei, M Tucker, C Kao, E Kinsey, B Rini, ... Targeted oncology 16 (5), 633-642, 2021 | 12 | 2021 |
| Salvage ipilimumab plus nivolumab after anti-PD-1/PD-L1 therapy in advanced hepatocellular carcinoma SL Alden, M Lim, C Kao, D Shu, AG Singal, A Noonan, P Griffith, M Baretti, ... Cancer Research Communications 3 (7), 1312-1317, 2023 | 8 | 2023 |
| Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma LC Brown, J Zhu, K Desai, E Kinsey, C Kao, YH Lee, S Pabla, ... Journal for immunotherapy of cancer 10 (10), 2022 | 8 | 2022 |
| Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors. C Kao, E Powers, MB Datto, M Green, MR Harrison, AJ Armstrong, ... Journal of Clinical Oncology 38 (5_suppl), 80-80, 2020 | 8 | 2020 |
| Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types. LC Brown, R Sedhom, EB Schwartz, J Zhu, C Kao, MD Tucker, M Labriola, ... Journal of Clinical Oncology 38 (15_suppl), 3007-3007, 2020 | 6 | 2020 |
| A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab … LC Brown, K Desai, C Kao, EN Kinsey, P Healy, J Kephart, MR Harrison, ... Journal of Clinical Oncology 38 (6_suppl), 637-637, 2020 | 4 | 2020 |
| A complete response after pseudo-progression: pembrolizumab for metastatic Squamous Cell Carcinoma (SCC) of the bladder C Kao, M McNamara, C Alley, N Spector, S Jauhari, RT Gupta, T Zhang, ... Clinical Genitourinary Cancer 17 (3), e672-e677, 2019 | 4 | 2019 |
| Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L) 1 blockade. SL Alden, M Lim, C Kao, D Shu, AG Singal, AM Noonan, P Griffith, ... Journal of Clinical Oncology 41 (16_suppl), 4091-4091, 2023 | 3 | 2023 |
| An illustrative case of combination cabozantinib/nivolumab for progressive metastatic renal cell carcinoma (mRCC) C Kao, DJ George, T Zhang The Oncologist 26 (3), e508-e511, 2021 | 3 | 2021 |
| Immune checkpoint inhibitor response in tumors with LRP1B variants. J Zhu, MD Tucker, C Kao, M Labriola, S Cheris, MB Datto, Y Wu, P Healy, ... Journal of Clinical Oncology 37 (15_suppl), e14291-e14291, 2019 | 3 | 2019 |
| Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus … MD Tucker, LC Brown, C Kao, N Hirshman, EN Kinsey, YW Chen, ... Journal of Clinical Oncology 39 (15_suppl), 4563-4563, 2021 | 2 | 2021 |
| Combination cabozantinib and nivolumab treatment in patients with refractory metastatic renal cell carcinoma (mRCC) E Kinsey, L Brown, C Kao, P Healy, M Harrison, M McNamara, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | 2 | 2019 |
